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Introduction. Oligometastatic disease it is a common situation in our daily clinical practice. Non-invasive treatments as a SBRT
can be a feasible therapeutic choice. We present our preliminary experience using single fraction of 34Gy in solitary lesions
localized in Lung.
Objectives. Main aim of this report is to show that single fraction of 34Gy in lung is a feasible treatment for pulmonary lesions in
oligometastatic patients with low rates of acute toxicity.
Material and methods. Seven patients with 7 pulmonary lesions were treated with a single dose of 34Gy. Inclusion criteria were:
lesion size smaller than 2 cm, distance from the chest wall and main bronchus tree higher than 2 cm, primary tumor under
control in PET scan.Mean age 61.57 y (r39–82), Gender distribution 3women and 4men, Histology: 4 cases (57.14%weremetastatic
lesions from colon), 1 metastatic from Adenoid Cystic, 1 Adenocarcinoma from Lung and 1 NSCLC. All patients underwent 4DCT
for contouring. Inmobilization was done by thermoplastic mask (Lorca Marin). Dosimetric characteristics: Mean volume of GTV
1.46 cm3 (r0.6–4.1), mean volume of PTV 11.29 cm3 (r7.1–22.2), D Max oesophagus 5.06 (r2.6–8.4), D max Heart 4.05 (r6.86–17.0), D
max trachea 5.12Gy (r0.3–11.1), Dmax skin 10.98 (r7.0–14.4). Patientswere treated using True Beammachine. In 6 cases treatments
were delivered without ﬂattering ﬁlter.
Results. After 3 months of follow up (r6–2.19) no toxicity higher than grade 2 was detected. Local control and survival rates are
100%, 100% respectively. To sum up, even this is a preliminary study, seems that long-term results can show us a new perspective
in these oligometastatic patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.319
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Purpose. To report experience treating lung cancer lesions by SBRT in Hospital Ramón y Cajal, Madrid.
Patients and methods. We report data of 19 lung cancer lesions (18 stages I and II a, non small cell lung cancer and 1 colon cancer
metastases), in patients treated between 2011 and 2012 by SBRT. All the lesions were less than 5 cm. PET-CT was carried out to
all patients for staging. The immobilization system used was dampening. SBRT was performed with three different schedules,
depending on the size and location of the tumor: 3 fractions of 20Gy, 5 fractions of 12Gy and 8 fractions of 7.5Gy. Daily control
with cone-beam CT was used. Initially, two-monthly follow-up was carried out with CT scans and PET/CT, alternatively.
Results. Mean age was 74.6 years, 18 men (94.7%) and 1 woman (5.3%). Tumor location: central in 4 patients (21.1%), medium in
10 (52.6%) and peripheral in 5 (26.3%). The tumor size range was between 12 and 48 mm: eight patients T1a (42.1%), 5 patients
T1b (26.3%), 5 patients T2a (26.3%) and 1 patient with a metastasis of 2 cm. Four patients (21.1%) were treated with 3 fractions of
20Gy; nine patients (47.4%) with 5 fractions of 12Gy and six (31.6%) received 8 fractions of 7.5Gy. Acute side effects were mild: Rib
fracture in 1 patient, and grade 2 local dermatitis, in 2 patients. The median follow-up was 11 months. Local control were 88.4%.
Distant metastases were seen in 3 patients (15.7%), 2 of them with local control. Overall survival rates were 94.7%. Disease-free
survival rates were 73.6%.
Conclusion. SBRT can be performed in an easy and comfortable way. Using a moderate dose schedule, SBRT is a well-tolerated
treatment and it leads to a favorable tumor control.
http://dx.doi.org/10.1016/j.rpor.2013.03.320
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Introduction. Stereotactic body radiation therapy (SBRT) requires to reach an exquisite immobilization and image control intra-
fraction, to deliver a conformal highly dose with high accuracy.
Objective(s). Describe the implementation of SBRT technique and to provide our preliminary clinical results using Helical
Tomotherapy (HT) for lung lesions.
Materials/methods. From August 2011 to January 2013, ﬁve patients with 8 non-central lung lesions (early-stage lung cancer n=3,
metastatic lesions n=5, all < 5 cm), medically inoperable, were treated with HT-SBRT. The sum of gross tumor volume (GTV)
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delineated on 4 kilovoltage-CT: Inspiration, expiration and free-breath± contrast by using Civco® Pro-lok abdominal compres-
sion system, was the internal tumor volume (ITV). Planned treatment volume (PTV) consisted of 5-mm radial and a 10-mm
craniocaudal expansion of ITV. The prescribed doses were: 3×20Gy, 3×18Gy, 8×7.5Gy. Dose constraints to normal tissue were
deﬁned accord to RTOG 0236 protocol. To asses intrafraction tumor motion, megavoltage-CT (MVCT) scan was obtained prior to
and at the end of each fraction (in patients receiving 18–20Gy/fraction a MVCT was performed in the middle of the delivered
treatment). The prior MVCT was matched with the kilovoltage-CT planning to check if corrections had to be done.
Results. The mean fraction treatment time was 1Gy/1 min. In 2 patients multiple targets were simultaneously treated. To asses
intra-fraction tumor motion we matched prior-MVCT, mid-MVCT and end-MVCT scan and we checked that PTVs were included
within isodose of prescription dose in all cases. Mean correction after MVCT registration was 2 mm. One late ﬁbrosis with
transitory neuroalgic pain has been observed. All lesions are controlled at the time of analysis and one patient died by other
causes and four patients are alive with disease.
Conclusions. HT-SBRT is feasible and well tolerated treatment in lung tumors and image guidance with MVCT allowed daily
position correction and precise treatment delivery.
http://dx.doi.org/10.1016/j.rpor.2013.03.321
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Introduction. Stereotactic body radiotherapy is an emergingnoninvasive technique for the treatment of lung lesions.Whenpatients
with non-small lung cancer are unable to tolerate the rigors of surgery due to lack of adequate respiratory reserve, SBRT offers
a radical option of treatment.
Objective. To describe and evaluate initial experience of SBRT for medically inoperable primary or recurrent lung cancer at our
institution.
Material/Methods. From May’12 to January’13, 15 lesions in 13 patients were irradiated. 2/13 patients presented recurrent lung
cancer and they had been previously irradiated. All patients had difﬁculty breathing. Each patient was immobilized with abdom-
inal compressor and vacuum cushion. An ITV was deﬁned using three CT scans with references to the phases of respiration and
the PTV was obtained by uniformly 5 mm ITV expanding. The dose to PTV was escalated from 50 to 60Gy in 5 fractions mainly.
8 patient treatments were perfomed on a Clinac iXTM and 5 treatments on a TruebeamTM with high deﬁnition MLC. Volumetric
modulated arc therapy (RapidArcTM) was used in 12/13 patients, and image-guided RT was performed with cone-beam CT (CBCT).
Intra-fraction movement was controlled by post-treatment CBCT.
Results. Median age was 74 (46–87). The median GTV/PTV size was 17.77/77.48 cm3 (1.28–129.95/18.08–263.39). The median D95%
of the PTV was 53.34Gy and median V20, V10 and V5 of both lungs were 7.38%, 13.8% and 23.8% respectively. Intra-fraction
movement in all cases was less than 2.4 mm. Only one patient presented deterioration of his usual dyspnea. Clinical outcomes
of 7 patients with more than 3 months of follow-up were collected. At a median follow-up of 6 (3–8) months, no local progression
was observed with 3/7 complete responses. Regional and distant failure were developed by 2 and 1 patients respectively.
Conclusions. Although the short follow-up, SBRT seems an effective and safe option for medically inoperable lung cancer patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.322
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Introduction. We present a series of patients treated with lung SBRT introduced in our clinics since 2009 to date. Target Analyze
dosimetric aspects, acute toxicity and response obtained.
Materials and methods. CT-simulation c/c IV (slice thickness) with body stereotactic body frame (ELEKTA®) mattress individualized
and diaphragmatic compression. Post-immobilization ﬂuoroscopy to determine three-dimensional displacement and decides
PTV margins. Use lung-window/level for Identify the lesion. Image Fusion (PET-CT). SYNERGY® multi-energy linear accelerator.
Isocenter stereotactic localization (Dynatrac®). Robotic table (6 degrees of freedom-Hexapod®). Image-guided Radiotherapy (IGRT)
cone beam. We performed 30 treatments in 13 patients (p) 7 with several locations: 6 p 2–5 lesions treated and 1 simultaneous
multiplemetastaseswas treated three times from2009 to 2012 (melanoma). 5 treatments are primary,metastatic rest. Histology: 2
